Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: a month ago

Possible Interaction: Glucose and Exenatide

supplement:

Glucose

Research Papers that Mention the Interaction

Exenatide is a long acting analogue of Glucagon-like peptide-1 (GLP-1) that augments glucose induced insulin secretion, and may increase beta cell mass.
Transplantation  •  2007  |  View Paper
OBJECTIVE In patients with type 2 diabetes, exenatide reduces A1C, postprandial and fasting glucose , and weight.
Diabetes care  •  2007  |  View Paper
RESULTS Monotherapeutic treatment with 10 microg of exenatide twice-daily for 28 days resulted in significant mean reductions in glycosylated hemoglobin (A1C) of -0.4 +/- 0.1% and fasting plasma glucose of -36.1 +/-
Diabetes technology & therapeutics  •  2007  |  View Paper
“We found that when the participants had an exendin 9 infusion at the same time as a glucose drink , they did not produce as much insulin and did not develop hypoglycaemia,” explains Gribble.
Nature Reviews Endocrinology  •  2019  |  View Paper
The aim of this study was to investigate whether Ex-4 alleviates the inhibition of high glucose on the proliferation and osteogenic differentiation of PDLSCs.
Archives of oral biology  •  2018  |  View Paper
CONCLUSION Exendin-4 can regulate ECM metabolism in HMC cultured in high glucose by inhibiting TGFβ1/ERK pathway, suggesting the beneficial effects of exendin-4 in preventing and treating diabetic nephropathy.
Nan fang yi ke da xue xue bao = Journal of Southern Medical University  •  2016  |  View Paper
EX decreased Hep-IR (197 ± 28 to 130 ± 37; P = 0.02) and increased HGU of orally administered glucose (23 ± 4 to 232 ± 89 [μmol/min/L]/[μmol/min/kg]; P = 0.003) despite lower insulin (23 ± 5 vs. 41 ± 5 mU/L; P < 0.02).
EX reduced RaO, resulting in reduced plasma glucose and insulin concentration from 0 to 120 minutes postglucose ingestion.
Hepatology  •  2016  |  View Paper
FG was lower with exenatide than lispro (6.5 vs. 7.2 mmol/L; P = 0.002).
Diabetes care  •  2014  |  View Paper
CONCLUSIONS These findings demonstrate that in persons with early T2DM, chronic treatment with exenatide enhanced ISR and increased β-cell sensitivity to glucose.
CONCLUSIONS These findings demonstrate that in persons with early T2DM, chronic treatment with exenatide enhanced ISR and increased β-cell sensitivity to glucose.
The higher dose of exenatide was associated with a significant improvement in β-cell sensitivity to glucose.
The higher dose of exenatide was associated with a significant improvement in β-cell sensitivity to glucose.
Clinical endocrinology  •  2014  |  View Paper
BACKGROUND Exenatide , a glucagon-like peptide-1 receptor agonist administered by self-injection, decreases plasma glucose , glycosylated hemoglobin (HbA1c), and weight in patients with type 2 diabetes.
Clinical therapeutics  •  2013  |  View Paper
Show More